Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$2.65 USD
+0.02 (0.76%)
Updated Sep 26, 2024 03:59 PM ET
After-Market: $2.65 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
GALT 2.65 +0.02(0.76%)
Will GALT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GALT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GALT
Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross
What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
GALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now
Other News for GALT
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q2 2024
Galectin Therapeutics GAAP EPS of -$0.20
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Galectin Therapeutics reports Q2 EPS (20c) vs. (15c) last year